A new review argues that lipid nanoparticles, already clinically validated as mRNA carriers, could unify cancer therapy ...

Farber-led Immunity study shows that p53-mutant cancers can evade T-cell detection through several mechanisms, while ...

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a new strategy to make cancer-fighting ...

Schematic illustrating the effects of p53C and M237I in driving the conversion of p63C and p73C droplets into amyloid aggregates at physiologically relevant temperatures. Heparin prevents the ...

In the 1970s, scientists knew that some viruses and chemicals caused cancer, but they didn’t know how. Arnold Levine, a biologist currently at the Institute for Advanced Study researched DNA viruses ...

A protein famed among scientists and clinicians for its ability to suppress the development of many types of tumors may just be moonlighting as a cancer fighter, a recent study by researchers at ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled "Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells." Researchers ...

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see. New research from Dana-Farber Cancer Institute ...

PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by rezatapopt’s 46% response rate and 10-month median duration in Y220C-mutant ovarian cancer. PMVP’s medicinal chemistry leverages the ...